Technical Analysis for ATRA - Atara Biotherapeutics, Inc.

Grade Last Price % Change Price Change
C 14.94 -1.84% -0.28
ATRA closed up 2.08 percent on Wednesday, January 19, 2022, on approximately normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Flat Down Down
Historical ATRA trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish -1.38%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.38%
Crossed Above 200 DMA Bullish -1.38%
Fell Below 200 DMA Bearish 0.67%
Fell Below 20 DMA Bearish 0.67%
180 Bearish Setup Bearish Swing Setup 0.67%
Inside Day Range Contraction 0.67%
Oversold Stochastic Weakness 0.67%
Slingshot Bearish Bearish Swing Setup -6.60%
Crossed Above 200 DMA Bullish -6.60%
Older End-of-Day Signals for ATRA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Non-ADX 1,2,3,4 Bearish Retracement Entry about 2 hours ago
Fell Below Previous Day's Low about 2 hours ago
Down 2 % about 2 hours ago
Down 1% about 2 hours ago
10 DMA Resistance about 2 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Solid Tumors Drugs Clinical Development Ovarian Cancer Targeted Therapy Renal Disease End Stage Renal Disease Stage Renal Disease

Is ATRA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.85
52 Week Low 11.81
Average Volume 711,671
200-Day Moving Average 15.18
50-Day Moving Average 16.68
20-Day Moving Average 15.95
10-Day Moving Average 15.34
Average True Range 1.04
ADX 12.04
+DI 19.37
-DI 20.18
Chandelier Exit (Long, 3 ATRs) 14.64
Chandelier Exit (Short, 3 ATRs) 17.04
Upper Bollinger Bands 17.68
Lower Bollinger Band 14.23
Percent B (%b) 0.29
BandWidth 21.67
MACD Line -0.43
MACD Signal Line -0.36
MACD Histogram -0.0636
Fundamentals Value
Market Cap 1.18 Billion
Num Shares 77.7 Million
EPS -6.07
Price-to-Earnings (P/E) Ratio -2.51
Price-to-Sales 0.00
Price-to-Book 5.14
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.89
Resistance 3 (R3) 16.97 16.49 16.61
Resistance 2 (R2) 16.49 16.07 16.45 16.51
Resistance 1 (R1) 15.86 15.81 16.18 15.78 16.42
Pivot Point 15.38 15.38 15.54 15.34 15.38
Support 1 (S1) 14.75 14.96 15.07 14.67 14.02
Support 2 (S2) 14.27 14.70 14.23 13.93
Support 3 (S3) 13.64 14.27 13.83
Support 4 (S4) 13.56